Malpas, Charles B.
Roos, Izanne
Sharmin, Sifat
Buzzard, Katherine
Skibina, Olga
Butzkueven, Helmut
Kappos, Ludwig
Patti, Francesco
Alroughani, Raed
Horakova, Dana
Havrdova, Eva Kubala
Izquierdo, Guillermo
Eichau, Sara
Hodgkinson, Suzanne
Grammond, Pierre
Lechner-Scott, Jeannette
Kalincik, Tomas http://orcid.org/0000-0003-3778-1376
,
Funding for this research was provided by:
National Health and Medical Research Council (1129189, 1140766, 1080518)
University of Melbourne
Article History
Accepted: 3 February 2022
First Online: 18 March 2022
Declarations
:
: Open Access funding enabled and organized by CAUL and its Member Institutions.
: Charles Malpas, Sifat Sharmin, Olga Skibina and Sara Eichau report no conflicts of interest. Izanne Roos received conference travel support and/or speaker honoraria from Biogen, Novartis, Roche, Merck and Sanofi-Genzyme and has received research support from MSIF, ARSEP and the University of Melbourne. Katherine Buzzard received honoraria and consulting fees from Biogen, Teva, Novartis, Genzyme-Sanofi, Roche, Merck, CSL and Grifols. Helmut Butzkueven served on scientific advisory boards for Biogen, Novartis and Sanofi-Aventis and has received conference travel support from Novartis, Biogen and Sanofi Aventis. He serves on steering committees for trials conducted by Biogen and Novartis, and has received research support from Merck, Novartis and Biogen. Ludwig Kappos received research support from Acorda, Actelion, Allozyne, BaroFold, Bayer HealthCare, Bayer Schering, Bayhill Therapeutics, Biogen, Elan, European Union, Genmab, Gianni Rubatto Foundation, GlaxoSmithKline, Glenmark, MediciNova, Merck , Novartis, Novartis Research Foundation, Roche, Roche Research Foundation, Sanofi-Aventis, Santhera, Swiss MS Society, Swiss National Research Foundation, Teva Neuroscience, UCB and Wyeth. Francesco Patti received speaker honoraria or advisory board fees from Almirall, Bayer, Biogen, Celgene, Merck, Myalin, Novartis, Roche, Sanofi-Genzyme and TEVA. He received research funding from Ministero Italiano della Universit‡ e della Ricerca Scientifica, Fondazione Italiana Sclerosi Multipla, Biogen and Merck. Raed Alroughani received honoraria as a speaker and for serving on scientific advisory boards from Bayer, Biogen, GSK, Merck, Novartis, Roche and Sanofi-Genzyme. Dana Horakova received speaker honoraria and consulting fees from Biogen, Merck, Teva, Roche, Sanofi Genzyme and Novartis, as well as support for research activities from Biogen and the Czech Ministry of Education (project Progres Q27/LF1). Eva Kubala Havrdova received speaker honoraria and consultant fees from Actelion, Biogen, Celgene, Merck, Novartis, Roche, Sanofi and Teva, and support for research activities from the Czech Ministry of Education (project Progres Q27/LF1). Guillermo Izquierdo received speaking honoraria from Biogen, Novartis, Sanofi, Merck, Roche, Almirall and Teva. Suzanne Hodgkinson received honoraria and consulting fees from Novartis, Bayer Schering and Sanofi, and travel grants from Novartis, Biogen Idec and Bayer Schering. Pierre Grammond is a Merck, Novartis, Teva-neuroscience, Biogen and Genzyme advisory board member, a consultant for Merck, received payments for lectures by Merck, Teva-Neuroscience and Canadian Multiple Sclerosis Society, and received grants for travel from Teva-Neuroscience and Novartis. Jeannette Lechner-Scott accepted travel compensation from Novartis, Biogen and Merck. Her institution receives the honoraria for talks and advisory board commitment from Bayer Health Care, Biogen, Genzyme Sanofi, Merck, Novartis and Teva, has been involved in clinical trials with Biogen, Novartis and Teva. Tomas Kalincik served on scientific advisory boards for Roche, Celgene, Sanofi-Genzyme, Novartis, Merck and Biogen, served on a steering committee for Brain Atrophy Initiative by Sanofi-Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Genzyme-Sanofi, Teva, BioCSL and Merck and received research support from Biogen.
: Patient data were obtained from the international MSBase cohort study (WHO ICTRP ID: ACTRN12605000455662) (InternalRef removed). The study was approved by the Melbourne Health Research Ethics Committee and local ethics committees where relevant. All procedures in this study were in accordance with the 1964 Helsinki Declaration (and its amendments).
: Not applicable as data were collected retrospectively.
: Not applicable.
: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: Charles B. Malpas, Izanne Roos and Tomas Kalincik: conception and design of the study, acquisition, analysis, and interpretation of data, drafting and reviewing the manuscript. Sifat Sharmin: conception and design of the study, analysis, and interpretation of data, drafting and reviewing the manuscript. Katherine Buzzard, Olga Skibina, Helmut Butzkueven, Ludwig Kappos, Francesco Patti, Raed Alroughani, Dana Horakova, Eva Kubala Havrdova, Guillermo Izquierdo, Sara Eichau, Suzanne Hodgkinson, Pierre Grammond and Jeannette Lechner-Scott: conception and design of the study, acquisition, and interpretation of data, drafting and reviewing the manuscript. Charles Malpas conducted the primary statistical analyses.